Angiochem
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Angiochem sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Angiochem: 6 sponsored US clinical trials, none currently recruiting.
Angiochem sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors With and Without Brain Metastases, with 1 trials.
Upper-quartile sponsor footprint
Angiochem sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
NCT02048059
ANG1005 in Patients With Recurrent High-Grade Glioma
NCT01967810
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
NCT01497665
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
NCT01480583
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
NCT00539383
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
NCT00539344
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
Therapeutic Areas
How the Angiochem early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumors With and Without Brain Metastases (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Angiochem: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Angiochem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Angiochem page
6 registered trials is a research-attention snapshot, not an endorsement of Angiochem or any single study.
- None of Angiochem's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Solid Tumors With and Without Brain Metastases is the condition Angiochem studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors With and Without Brain Metastases trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Angiochem pipeline card: 6 registered trials from official public datasets.Report a data error.